The large majority of studies with sunitinib involved advanced and heavily treated breast cancer focusing on the HER2-negative (or trastuzumab (TZM) insensitive) subtypes (phase I [1], phases II [2, 3], phases III [4–6]). The gene discussed is ERBB2; the disease is breast carcinoma.